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Abstract Rationale: Drugs of abuse can affect the
functioning of the hypothalamic–pituitary–adrenal (HPA)
axis. Acute administration of drugs that serve as
reinforcers have been observed to stimulate the rat HPA
axis, leading to the suggestion that these stimulatory
effects may contribute to the development of drug-
maintained behaviors. Objectives: To determine whether
reinforcing drugs that are dissimilar with respect to their
mechanisms of action have similar effects on HPA axis
activity at doses that are self-administered. Rhesus
monkeys were randomly assigned to self-administer the
μ-opioid agonist fentanyl, the psychomotor stimulant
cocaine, or the NMDA antagonist ketamine. Methods:
Each monkey was trained to press a lever in order to
receive an intravenous injection of drug or saline. Blood
samples were obtained before, during, and after the self-
administration sessions and assayed for ACTH and
cortisol by radioimmunoassay. Results: Fentanyl, co-
caine, and ketamine were each self-administered across a
range of doses. However, the three drugs differed in their
effects on ACTH and cortisol. Cocaine stimulated ACTH
and cortisol secretion, a finding that is consistent with
previous rat and primate studies. Self-administration of
both fentanyl and ketamine inhibited HPA axis activity.
HPA inhibition by fentanyl is consistent with other
monkey and human studies, and contrasts with the
stimulatory effects of μ-opioids in rodents. The inhibitory
effect of ketamine on ACTH and cortisol secretion
contrasts with findings in the few primate studies that
have evaluated NMDA antagonists. Neither fentanyl nor
cocaine, at doses that maintained maximum rates of
responding, produced significant changes in ACTH and
cortisol levels. Conclusions: There appears to be little
commonality between different classes of abused drugs
and their effects on the HPA axis, which calls into question
the necessity for HPA axis stimulation in the reinforcement
of drug-maintained behavior.
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Introduction
Many drugs of abuse, such as psychomotor stimulants
(cocaine, amphetamine, and nicotine), depressants (mor-
phine and alcohol), and hallucinogens (LSD and N,N-
dimethyltryptamine) have been shown to affect hypotha-
lamic–pituitary–adrenal (HPA) axis activity (for review,
see Sarnyai et al. 2001). Although not typically thought of
as “stressors” in the aversive sense of the word, drugs of
abuse nevertheless induce physiological and psychological
changes that may activate homeostatic mechanisms such
as the HPA axis. Over the past decade, a theoretical
framework has evolved that incorporates the interaction of
drug reward with activation of the HPA axis. Studies that
highlight this research rely primarily on data obtained
from rats. For example, rats with a heightened HPA
response following exposure to novelty were reported to
acquire self-administration behavior for lower doses of
cocaine (Goeders and Guerin 1994), amphetamine (Piazza
et al. 1991), and heroin (Shaham and Stewart 1994).
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Adrenalectomized rats failed to acquire self-administration
behavior, implying that glucocorticoids, the end-product
of HPA axis stimulation, are necessary for the expression
of self-administration behavior in the rat (Goeders and
Guerin 1996). Piazza and le Moal (1996) have expanded
their hypothesis, which relates the response of rats to
novelty to their subsequent acquisition of drug-taking, to
include humans who engage in risk-taking behaviors. This
is based on the premise that risk-takers may be more likely
to engage in drug experimentation, resulting in their
greater vulnerability for drug abuse.
Although psychomotor stimulants such as cocaine and
amphetamine generally stimulate the HPA axis regardless
of the species and treatment regimen, the results of studies
involving HPA effects of drugs such as opioid agonists
and NMDA antagonists often conflict with one another. In
the opioid literature, the fundamental nature of the
disagreement appears to be species-dependent, as shown
by species differences in the relationship between the
endogenous opioid β-endorphin, CRH, and feeding
behavior. In the rat, intracerebroventricular administration
of corticotropin-releasing hormone (CRH) resulted in an
increase in plasma β-endorphin levels and a decrease in
food intake (Hotta et al. 1991). In primates, however, the
administration of β-endorphin led to a fall in CRH
secretion (Garland and Zis 1990) and an increase in food
intake (Nader and Barrett 1989). Opioids decrease ACTH
and cortisol secretion in humans (Gaillard et al. 1981;
Delitala et al. 1983; Allolio et al. 1987), whereas acute
morphine administration causes ACTH and corticosterone
to rise in rat, mouse, guinea pig, and cat (see review by
Pechnick 1993).
Non-competitive NMDA antagonists such as ketamine
and phencyclidine (PCP) also inhibit dopamine uptake,
although the majority of their behavioral effects appear to
be related to their activity at NMDA receptors (e.g. Koek
et al. 1989). With respect to the HPA axis effects of
NMDA antagonists, the findings are not always in
agreement even within species. NMDA itself has been
shown to stimulate ACTH release in rats (Iyengar et al.
1990; Farah et al. 1991; Jezova et al. 1991) and primates
(Gay and Plant 1987; Reyes et al. 1990). NMDA
antagonists such as AP5 and MK-801 block the
stimulatory effect of NMDA on ACTH in rats (Farah et
al. 1991; Jezova et al. 1991). However, anesthetizing
doses of the NMDA antagonists PCP or ketamine
produced increases in ACTH and cortisol when adminis-
tered to rhesus monkeys (Setchell et al. 1975; Elvidge et
al. 1976) or humans (Adams et al. 1992). It is possible that
the paradoxical effect of NMDA antagonists on HPA axis
function in primates may be based on the magnitude of the
dose and the duration of its administration.
Although there is some understanding of the ways in
which acute administration of drugs of abuse may alter
HPA axis function, there is an almost complete absence of
information as to how these drugs, at doses that are self-
administered, interact with stress hormone secretion. If
there is a role for the HPA axis in drug reward, it is
perhaps most meaningful to study it under conditions in
which the dose and delivery are guided by the subject’s
perception of the rewarding properties of the drug under
study. In the present paper, we have examined the
behavioral and HPA effects of fentanyl, a μ-selective
opioid agonist, cocaine, a psychomotor stimulant, and
ketamine, a non-competitive NMDA antagonist. Our
general hypothesis is that each of these drugs will produce
self-administration behavior over a range of doses, and
that despite their differing mechanisms of action, they will
produce similar effects on ACTH and cortisol secretion.
Materials and methods
Subjects
Eight adult male rhesus monkeys (Macaca mulatta),
weighing between 9.9 and 15.4 kg, and one female
monkey, weighing 8.2 kg, were the subjects for this study.
All subjects had an extensive self-administration history
with two or more classes of drugs, including cocaine and
methohexital. The monkeys were randomly assigned to the
three drug groups; cocaine (n=4), fentanyl (n=4), and
ketamine (n=4). One monkey (2489) was tested with all
three drugs, one monkey (female: 2487) was tested with
both fentanyl and ketamine, and one monkey (3151) was
tested with both cocaine and fentanyl. The remaining
monkeys were tested with only a single drug; cocaine
(monkeys 3603 and 3596), fentanyl (monkey 4395), and
ketamine (monkeys 3147 and 3579).
Apparatus
Each monkey was individually housed in a stainless steel
cage measuring 83.3×76.2×91.4 cm deep (Bryan Research
Equipment Corporation, Bryan, Tex., USA) located in a
laboratory that contained a total of 24 similarly housed
monkeys. The temperature in the room was maintained at
21°C, and lights were illuminated from 0630 hours until
1930 hours daily. The monkeys were fed 8–12 Purina
Monkey Chow biscuits twice daily and fruit once daily to
maintain normal adult weight; water was freely available.
Each monkey had an indwelling venous catheter in a
femoral, internal, or external jugular vein. Catheters were
inserted during aseptic surgery under ketamine (10 mg/kg)
and xylazine (2 mg/kg) anesthesia. Following placement
in the vein, the catheter was guided subcutaneously to the
midscapular region where it was externalized. The outer
portion of the catheter was protected inside the cage by a
flexible stainless steel tether, with one end attached to a
double layer polyester jacket (Lomir, New York, N.Y.,
USA) worn by the monkey and the other bolted to the rear
of the cage. Each cage had a 15×20 cm panel fixed to its
right wall. Each panel had three stimulus lights, two red
and one central green light, placed above two response
levers. The red stimulus light over the right lever signaled
drug availability. The green center light was illuminated
for the duration of the drug or saline injection, 1 ml per
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5 s. During a time out, all stimulus lights were
extinguished and responding had no programmed con-
sequences. The experiment was controlled by IBM/PS2
computers located in an adjacent room. The computers
were programmed using Med Associates software (Geor-
gia, Vt., USA).
Procedure
Drug self-administration sessions were scheduled twice
daily for 130 min starting at approximately 10 a.m. and
4 p.m. Saline was substituted on a frequent basis (25–50%
of sessions). The reinforcing effectiveness of and stress
hormone response to cocaine (0.001, 0.003, 0.01, 0.03,
and 0.1 mg/kg per injection), fentanyl (0.03, 0.1, 0.3, 1.0,
and 3.0 μg/kg per injection), and ketamine (0.003, 0.01,
0.03, 0.1, and 0.3 mg/kg per injection) were evaluated.
Drug or saline delivery was contingent on each monkey
emitting a fixed ratio of 30 lever presses (FR30) while the
red stimulus light was illuminated. Following completion
of the ratio, the red light was extinguished and the green
light was illuminated for the duration of the intravenous
injection of either drug or saline. There was a 10-s time out
between the end of an injection and the next response
opportunity. The 2 h 10 min session was divided into four
25-min components, each separated by a 10-min time out
during which venous blood was drawn. A single dose of
drug or saline was made available each session (two
sessions per day; 10 a.m. and 4 p.m.), and blood was
sampled during self-administration of each drug dose
during at least two morning self-administration sessions.
Blood was drawn after the lever press responses for each
drug dose had stabilized, usually after 4–7 days of drug
dose availability. The self-administration behavior of the
three monkeys that were tested with more than one drug
was allowed to stabilize for at least a week after switching
from one drug to another, and testing did not commence
until monkeys were responding reliably for the new drug.
A stable baseline of self-administration behavior was
defined as consistency (<15% variability in the number of
injection earned) across sessions. The order of presentation
of the drug doses was varied randomly. Blood was
sampled for the measurement of ACTH and cortisol at 15
and 5 min prior to the self-administration session, as well
as during (25, 60, 95, and 130 min) and after the session
(2 h 45 min, 3 h 20 min, 4 h 20 min, and 5 h 20 min). All
experiments reported in this study were conducted during
the morning self-administration session.
Blood collection and handling
Blood samples were collected from the monkeys in the
self-administration study via their indwelling venous
catheters. Prior to drawing each blood sample, a 3 ml
syringe was used to empty the contents of the catheter and
this fluid was discarded. Then each blood sample (1.1–
1.4 ml) was placed in a 2-ml Vacutainer (Becton
Dickinson and Company, Franklin Lakes, N.J., USA)
containing 0.04 ml of 7.5% EDTA and immediately placed
on ice. After a blood sample was drawn, 1.5–3 ml of
30 IU/ml heparin saline solution was injected into the
catheter. For blood samples drawn during the self-
administration session, drug solution sufficient to fill the
catheter lumen was also injected. Blood samples were
centrifuged at 4000 rpm for 5 min at 4°C and then the
plasma (0.7 ml) was pipetted into 2-ml Cryovials (Corning
Incorporated, Corning, N.Y., USA) and stored at −80°C
until assay. ACTH and cortisol levels were determined
using commercially available radioimmunoassay kits
(ACTH: Nichols Institute Diagnostics, San Juan Capis-
trano, Calif., USA; cortisol: Diagnostic Products Corpora-
tion, Los Angeles, Calif., USA). The limit of detection of
the cortisol assay was 0.2 ug/dl, while the intra-assay and
inter-assay coefficients of variation were 5 and 6.5%,
respectively. The limit of detection for the ACTH assay
was 0.5 pg/ml, with intra-assay and inter-assay coefficients
of variation of 3 and 7%, respectively.
Data analysis
Self-administration data (responses per second, mean
number of injections and drug intake) were obtained
from mornings during which blood samples were
collected. Response rate was calculated by dividing the
total number of lever presses executed during the session
by the cumulative time during which the red light was
illuminated. Data were averaged across subjects and
plotted against each dose of each drug. The data were
analyzed for dose dependency and for differences across
the sampling time.
ACTH and cortisol levels that were measured in plasma
during saline, fentanyl, cocaine, and ketamine self-
administration are presented as mean±standard error of
the mean (SEM). Initially the effects of saline self-
administration on ACTH and cortisol secretion among the
drug-taking groups were compared to ascertain that there
were no underlying differences. Then comparisons of the
HPA effects of saline and each drug dose within each of
the drug-taking groups were made. There was some
individual variation in the pre-session ACTH and cortisol
measurements. Therefore, the raw ACTH and cortisol data
for each drug dose were standardized by subtraction of the
averaged pre-session ACTH or cortisol value from the
subsequent data points prior to graphing and statistical
analysis. Except in the case of the saline comparison,
within-drug (but not between-drug) data analysis was
carried out.
Summary data are shown subsequent to calculation of
area under curve (AUC) values. AUC values are an
estimate of the total ACTH (pg.min/ml) and cortisol (ug.
min/dl) release during the self-administration session
relative to pre-session levels. AUC values were calculated
according to the trapezoidal rule (e.g. Tallarida and
Murray 1987). The dose-related effects of cocaine,
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fentanyl, and ketamine on ACTH and cortisol secretion
were examined separately for each drug.
Analysis of variance was conducted for all of the
comparisons described above, using one or two within-
subject variables (dose and sampling time) and one
between-subject variable (in the case of the saline
comparison across the different drugs). Where appropriate,
post hoc pairwise comparisons using the Tukey Honest
Significant Difference test of significance (P<0.05) were
carried out (Statistica v.5.0, Statsoft, Tulsa, Okla., USA).
Drugs
Cocaine and fentanyl were obtained from the National
Institute of Drug Abuse (Bethesda, Md., USA). Ketamine
was purchased from Vetpo (Holland, Mich., USA). Each
drug dilution was made using sterile saline.
Results
Fentanyl Responding for fentanyl generated a bell-shaped
function, with a significant effect of dose [F(5,15)=6.78,
P<0.05]. The maximum response rate was 1.04
±0.12 responses/s for injections of 0.1 μg/kg per injection
fentanyl. Total intake of fentanyl increased as a function of
the available dose, with peak intake ranging from 38 to
79 μg/kg when the highest dose (3.0 μg/kg per injection)
of fentanyl was available (Fig. 1a). ACTH and cortisol
secretion decreased during self-administration of 0.3, 1.0,
and 3.0 μg/kg per injection fentanyl [ACTH: F(5,15)
=5.84, P<0.05; Fig. 1b] and 1.0 and 3.0 μg/kg per
injection fentanyl [cortisol: F(5,15)=4.95, P<0.05; Fig. 1c]
relative to when only saline was available. When the
cumulative release of ACTH and cortisol was examined,
the AUC for both hormones diminished as the dose of
fentanyl increased [ACTH: F(5,10)=5.28, P<0.05; corti-
sol: F(5,10)=4.86, P<0.05; Fig. 1d]. Overall ACTH and
cortisol secretion were significantly attenuated when total
fentanyl intake equaled or exceeded 18.9±3.3 μg/kg. Self-
Fig. 1 a Response rate (responses/s) and drug intake (μg/kg) for
monkeys trained to lever press on a fixed ratio of 30 responses for
each injection of the μ-opioid agonist, fentanyl (μg/kg per injection)
or saline (n=4). b,c Plasma concentration of ACTH (b; baseline =
6.6±0.43 pg/ml) and cortisol (c; baseline = 12.3±0.88 μg/dl)
measured in venous blood samples obtained before, during, and
after sessions during which saline or fentanyl was available for self-
administration. d Cumulative release of cortisol (μg.min/dl) and
ACTH (pg.min/ml) during self-administration of fentanyl or saline.
The zero line on the Y-axis indicates the average pre-session
hormone levels. Key to symbols: (a) self-administration rates
significantly different from 0.03, 1.0, and 3.0 μg/kg per injection
fentanyl; (b) ACTH and cortisol levels significantly different from
0.1, 0.3, and 1.0 and (c) 3.0 μg/kg per injection fentanyl; (d) ACTH
and cortisol levels significantly different from 0.03 μg/kg per
injection fentanyl; (e) ACTH and cortisol levels significantly
different from 0.3, 1.0, and 3.0 μg/kg per injection fentanyl, P<0.05
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administration of the three largest doses of fentanyl (0.3,
1.0, and 3.0 μg/kg per injection) generated average intakes
equal to or greater than 18.9 μg/kg, and resulted in an
overall decrease in cortisol and ACTH secretion relative to
when saline was available. The inhibitory effects of
fentanyl intake on the HPA axis persisted for up to 2 h
following the cessation of the session.
Cocaine Responding for cocaine generated a bell-shaped
function, with a significant effect of dose [F(5,15)=8.62,
P<0.05]. The maximum response rate was 0.81
±0.06 response/s for injections of 0.01 mg/kg per injection
cocaine. Total intake of cocaine increased as a function of
the available dose, with peak intake ranging from 2.55 to
3.75 mg/kg when the highest dose (0.1 mg/kg per
injection) of cocaine was available (Fig. 2a). Cocaine
(0.03 and 0.1 mg/kg per injection) significantly increased
the secretion of ACTH relative to when saline, 0.001,
0.003, and 0.01 mg/kg per injection cocaine were
available (P<0.05; Fig. 2b). Cocaine, at the same doses
(0.03 and 0.1 mg/kg per injection), increased cortisol
secretion relative to when saline was available for self-
administration [F(5,15)=4.09, P<0.05; Fig. 2c]. When the
cumulative release of ACTH and cortisol was examined,
the AUC for both hormones increased as the dose of
cocaine increased [ACTH: F(5,15)=3.14, P<0.05; cortisol:
F(5,15)=7.53, P<0.05; Fig. 2d]. Overall, ACTH and
cortisol secretion was significantly increased when total
cocaine intake equaled or exceeded 1.84±0.28 mg/kg.
Self-administration of the two largest doses of cocaine
(0.03 and 0.1 mg/kg per injection) generated average
intakes equal to or greater than 1.84 mg/kg, and resulted in
an overall increase in cortisol and ACTH secretion relative
to when saline (ACTH and cortisol) or 0.003 mg/kg per
injection cocaine were available (cortisol only). The
stimulatory effects of cocaine intake on cortisol at the
0.03 and 0.1 mg/kg per injection doses persisted following
the cessation of the session, with post-session AUC
significantly elevated for these doses relative to when
saline, 0.001, 0.003, and 0.01 mg/kg per injection cocaine
had been self-administered [F(5,15)=5.20, P<0.05; data
not shown].
Fig. 2 a Response rate (responses/s) and drug intake (mg/kg) for
monkeys trained to lever press on a fixed ratio of 30 responses for
each injection of the psychomotor stimulant, cocaine (mg/kg per
injection) or saline (n=4). b,c Plasma concentration of ACTH (b;
baseline = 6.7±0.74 pg/ml) and cortisol (c; baseline = 11.3±0.56 μg/
dl) measured in venous blood samples obtained before, during, and
after sessions during which saline or selected doses of cocaine were
available for self-administration. d Cumulative release of cortisol
(μg.min/dl) and ACTH (pg.min/ml) during self-administration of
cocaine or saline. Key to symbols: (a) self-administration rates
significantly different from saline, 0.001, 0.03, and 0.1 mg/kg per
injection cocaine; (b) ACTH and cortisol levels significantly
different from saline, 0.001 or 0.003 mg/kg per injection cocaine;
ACTH and cortisol levels significantly different from saline (c)
0.001, 0.003 (d), and (e) 0.01 mg/kg per injection cocaine; (f)
Cortisol levels significantly different from saline and 0.003 mg/kg
per injection cocaine, P<0.05
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Ketamine Responding for ketamine generated a bell-
shaped function, with a significant effect of dose [F(5,15)
=3.39, P<0.05]. The maximum response rate was 1.77
±0.16 responses/s for injections of 0.03 mg/kg per
injection ketamine. Total intake of ketamine increased as
a function of the available dose, with peak intake ranging
from 10.1 to 18.9 mg/kg when the highest dose (0.3 mg/kg
per injection) of ketamine was available (Fig. 3a). ACTH
secretion decreased during self-administration of 0.03, 0.1,
and 0.3 mg/kg per injection ketamine [F(5,15)=3.61,
P<0.05; Fig. 3b] relative to when saline (0.1 mg/kg per
injection dose only) or 0.003 mg/kg per injection ketamine
was available. Cortisol secretion decreased during self-
administration of 0.1 and 0.3 mg/kg per injection ketamine
(P<0.05; Fig. 3c) relative to when 0.003 mg/kg per
injection ketamine was available. When the cumulative
release of ACTH and cortisol was examined, the AUC for
both hormones diminished as the dose of ketamine
increased [ACTH: F(5,15)=6.97, P<0.05; cortisol: F
(5,15)=5.41, P<0.05; Fig. 3d]. Self-administration of
0.1 mg/kg per injection ketamine (total intake = 10.2
±2.3 mg/kg) resulted in a decrease in cortisol and ACTH
release relative to when saline, 0.003 and 0.01 mg/kg per
injection ketamine were available. The inhibition of
cortisol and ACTH measured while ketamine was being
actively self-administered did not persist once the session
had ended.
Saline ACTH and cortisol secretion were compared during
the sessions in which saline was self-administered by
monkeys from the fentanyl, cocaine, and ketamine groups,
with drug group as the between-subjects factor. The
secretory patterns of ACTH and cortisol during saline self-
administration did not differ among the drug groups,
although there was an effect of sampling time [ACTH: F
(7,56)=6.48, P<0.05; cortisol: F(7,56)=7.14, P<0.05]
which indicated that both ACTH and cortisol levels were
elevated relative to the pre-session levels from 95 to
200 min (i.e. from half way through the session until
70 min after the session). This effect of saline was
unrelated to the drug being tested in these monkeys.
Fig. 3 a Response rate (responses/s) and drug intake (mg/kg) for
monkeys trained to lever press on a fixed ratio of 30 responses for
each injection of the NMDA antagonist, ketamine (mg/kg per
injection) or saline (n=4). b,c Plasma concentration of ACTH (b;
baseline = 6.2±0.42 pg/ml) and cortisol (c; baseline = 15.1±0.57 μg/
dl) measured in venous blood samples obtained before, during, and
after sessions during which saline or selected doses of ketamine
were available for self-administration. d Cumulative release of
cortisol (μg.min/dl) and ACTH (pg.min/ml) during self-administra-
tion of ketamine or saline. Key to symbols: (a) self-administration
rates significantly different from saline, 0.003 and 0.3 mg/kg per
injection ketamine; ACTH and cortisol levels significantly different
from (b) 0.3, (c) 0.1, and (d) 0.03 mg/kg per injection ketamine; (e)
ACTH levels significantly different from saline; (f) ACTH and
cortisol levels significantly different from saline, 0.003 and 0.01 mg/
kg per injection ketamine, P<0.05
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Discussion
This study was designed to measure the effects of self-
administered drugs of abuse on the HPA axis hormones,
ACTH and cortisol, in rhesus monkeys. The monkeys
tested in this study reliably self-administered fentanyl,
cocaine, and ketamine, generating a bell-shaped function
of response rates across a range of doses for each drug. In
addition, each self-administered drug changed the plasma
concentrations of the HPA axis hormones, ACTH and
cortisol. Intake of the psychomotor stimulant, cocaine,
resulted in stimulation of ACTH and cortisol secretion,
whereas the μ-opioid agonist, fentanyl, and the NMDA
antagonist, ketamine, both attenuated HPA axis activity.
Despite the differences in their modulation of HPA axis
activity, neither fentanyl nor cocaine, at doses that
maintained maximum rates of responding, produced
significant changes in ACTH and cortisol levels. These
findings are at odds with our hypothesis that drugs of
abuse, at doses that are self-administered, would stimulate
HPA axis activity regardless of their mechanism of action.
Saline self-administration appeared to stimulate the
secretion of both ACTH and cortisol in monkeys also self-
administering fentanyl, a stimulatory effect that is
probably due to the increase in behavioral activity
measured at the start of all sessions. However, a compar-
ison of ACTH and cortisol secretion during saline
availability in monkeys trained to self-administer cocaine,
ketamine, or fentanyl, showed that there were no differ-
ences in their hormone responses to saline. Hence for the
monkeys in each drug group, the HPA response to saline
was used as the basis for comparison for the effects of
drug on ACTH and cortisol secretion. Each of the
monkeys tested in the present study had a similar drug
history, having had the opportunity to self-administer both
cocaine and methohexital on previous occasions. The four
subjects in each group were consistent with respect to their
drug and dose-appropriate behavioral and endocrinologi-
cal responses to each of the test drugs. It is unlikely that
differences in drug history affected the results of the
present study since subjects were randomly assigned for
testing with each of the drugs.
Self-administration of fentanyl reduced both ACTH and
cortisol secretion, and this effect persisted for several
hours after the session had ended. There appeared to be a
floor to this effect, however, as intakes exceeding 19 μg/
kg produced similar reductions in the release of both
hormones. Tolerance and dependence to fentanyl were
unlikely to have developed during this study. The doses
that were available were small, and the drug sessions were
alternated with saline on a regular basis (saline was
available during approximately 50% of the sessions). It
has been demonstrated in our laboratory that a dose of
0.04 mg/kg fentanyl given every 6 h produces dependence
after a month (J. Woods, personal communication). In our
study, monkeys earned between 0.04 and 0.08 mg/kg
fentanyl only when the largest dose (3.0 ug/kg per
injection) was available, but this dose was self-adminis-
tered only once every 24 h during the weeks in which it
was being tested, with saline available during the
remaining session each day. While no comparable study
has been carried out in non-human primates, our finding
that a μ-opioid agonist such as fentanyl inhibits the release
of ACTH and cortisol is consistent with work published in
humans (Gaillard et al. 1981; Rittmaster et al. 1985;
Allolio et al. 1986; Garland and Zis 1989). For example,
intravenous morphine blunted the effect of intravenous
oCRH in humans (Rittmaster et al. 1985), and an
intramuscular injection of the enkephalin analog, FK 33-
824, attenuated the stimulatory effect of h/rCRH on
ACTH, β-endorphin, and cortisol secretion in humans
(Allolio et al. 1986). In work done using rodents, there is
general agreement that acute administration of opioid
agonists in vivo increases rather than decreases ACTH and
corticosterone (e.g. Hayes and Stewart 1985). To date,
there have been no studies in rats that describe the HPA
effects of doses of opioids that reinforce behavior. On the
basis of our findings in the present study, we would predict
that small opioid doses that serve as reinforcers in the rat
would fail to stimulate plasma concentrations of ACTH
and corticosterone.
Cocaine stimulated ACTH and cortisol release at the
two highest doses, both of which were contained in the
descending limb of the dose–response function. This
stimulation occurred following total drug intakes in excess
of 1.8 mg/kg. This finding is similar to what we have
published previously using a different schedule of rein-
forcement (Broadbear et al. 1999a). Another interesting
similarity between our present and previous studies is that
both studies feature doses of cocaine that maintained self-
administration behavior yet did not result in significant
activation of the HPA axis. In the present study, 0.01 mg/
kg per injection cocaine maintained the highest rates of
responding but did not differ from saline in its effects on
ACTH and cortisol. Total cocaine intake at this dose was
1.1±0.18 mg/kg. Activation of the HPA axis by cocaine
has also been reported in rats (Moldow and Fischman
1987; Rivier and Vale 1987; Galici et al. 2000) and in
human subjects (Mendelson et al. 1989; Vescovi et al.
1992; Heesch et al. 1995). Cocaine has been shown to
cause the release of CRH in hypothalamic cells in vitro
(Calogero et al. 1989). While there is evidence supporting
the potential importance of HPA hormone feedback during
cocaine self-administration in rats (Shaham et al. 1998;
Goeders and Guerin 2000), few studies have attempted to
address the role of HPA hormones in rhesus monkeys and
humans. In the monkey, it has been shown that acute
pharmacological antagonism of cortisol synthesis as well
as antagonism of CRH at the level of the pituitary did
nothing to disrupt ongoing self-administration of cocaine
(Broadbear et al. 1999b). Similarly, pretreatment with
ketoconazole, a cortisol synthesis inhibitor, prior to
administration of cocaine did not diminish the subjective
reinforcing effects of cocaine in experienced users (Ward
et al. 1998). Studies designed to address the role of HPA
axis hormones in the acquisition or reinstatement of
cocaine-maintained behavior in humans or non-human
primates have yet to be conducted.
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Ketamine, at doses that maintained responding, inhib-
ited ACTH and cortisol secretion. This inhibition appeared
maximal at intakes exceeding 4.5 mg/kg. As with fentanyl,
the low basal levels of ACTH and cortisol prior to the
session may have precluded the measurement of further
decreases as intake increased. There are some data in
rhesus monkeys (Setchell et al. 1975; Elvidge et al. 1976)
and humans (Adams et al. 1992) with which to compare
our findings. In these studies, the HPA axis effects of large
doses of ketamine or phencyclidine, sufficient to produce
anesthetization, were reported. Anesthetic doses and self-
administered intake of ketamine are remarkably similar.
The average intake of ketamine at the largest dose (0.3 mg/
kg per injection) was in the vicinity of 14 mg/kg in the
present study. A single injection of 10 mg/kg ketamine is
sufficient to produce anesthesia in rhesus monkeys (e.g.
present study). In the study by Setchell et al. (1975), a fall
in cortisol was measured in all subjects during the first
60 min after phencyclidine injection, which is consistent
with the findings of the present study. It is only after a
more prolonged period of anesthetization (and additional
dosing with phencyclidine) that the cortisol levels began to
increase. It is therefore possible that drug dose and
duration of action are important determinants in the effects
that NMDA antagonists have on ACTH and cortisol
secretion.
Although data from this study indicate that different
drugs of abuse may have opposing effects on HPA axis
activity, they do not exclude the possibility that interac-
tions with the HPA axis still do underlie some aspects of
the rewarding properties of these drugs (for instance, to
promote normalization of the HPA axis during or
following the application of a stressor). There is also the
possibility that drug-associated reinforcement may corre-
late with the activation of ascending CRH pathways to
brain reward areas such as the nucleus accumbens (Lu et
al. 2003), and this activation may not be reflected by a
corresponding rise in pituitary–adrenal hormones.
Although answering this question is beyond the scope of
the present study, the lack of evidence for HPA activation
in the peripheral circulation does not discount a possible
role for CRH in the central nervous system. Our findings
in rhesus monkeys do, however, undermine the premise
that a stimulation of the HPA axis is necessary for
mediating drug reward (Sarnyai et al. 2001). Clearly, two
of the three drugs tested in this study attenuated rather than
stimulated basal ACTH and cortisol secretion over a range
of self-administered doses. In the primate, as well as the
rat, drug-taking history may be critical with respect to the
role of the HPA axis in the reinforcement of drug-taking
behavior. The case for critical involvement of the HPA
axis is far stronger with respect to acquisition and
reinstatement of self-administration behavior in rats (e.g.
Piazza and le Moal 1996; Shaham et al. 1998). Since no
one has addressed these aspects of drug-maintained
behavior in primates, our conclusion that there is no
apparent role for the HPA axis in the self-administration of
drugs of abuse may only apply to the case in which drug-
maintained behavior is already established and remains
stable over time.
The present study takes our understanding of reinforce-
ment and HPA axis activation to the next level with the
addition of fentanyl and ketamine data to our current and
earlier work with cocaine. In contrast to cocaine, both
fentanyl and ketamine inhibited the HPA axis, which
makes a simple relationship between the stress axis and
substance abuse unlikely. As with cocaine, the intake of
fentanyl at doses that maintained peak levels of respond-
ing did not produce a significant change in either ACTH or
cortisol. It was only the higher doses on the descending
limb of the dose–response function that produced signif-
icant change. This suggests a connection between the rate-
limiting properties of each drug and a change in ACTH
and cortisol release, but in terms of reinforcement, there is
no change in HPA axis activity that appears to be a
requirement for the self-administration of these mechan-
istically different drugs of abuse.
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